Interpretation of whether vorasidenib-VORANIGO has been included in medical insurance and reimbursement policies

Vorasidenib (trade name VORANIGO) is a new oral dual IDH1/2 inhibitor, mainly used to treat patients with brain tumors and leukemia with specific gene mutations. The drug inhibits the activity of IDH1/2 mutant enzymes and blocks carcinogenic metabolic pathways, thereby delaying tumor progression. Internationally, vorsidenib has been approved by the drug regulatory authorities of some countries for the treatment of tumors targeting IDH mutations, but it has not yet been officially launched in China.

Since Voxanib is not available in mainland China, it has not yet been included in the medical insurance system and there is no official domestic price. This means that domestic patients cannot obtain drugs through medical insurance reimbursement and need to obtain them through special channels, such as overseas purchasing or participation in clinical trials. For patients who need treatment with this drug, this not only increases the cost of treatment, but also places higher demands on the legality and safety of drug sources.

In overseas markets, the original US version of Voxanib is 40mg*30 tablets, and the price per box may be as high as more than 380,000 yuan. The price will fluctuate due to exchange rates and regional policies. In order to reduce the cost of medication for patients, generic drugs have also appeared on the market in some countries or regions. For example, voxanib of the same specification produced by Lucius Pharmaceuticals in Laos sells for about more than 7,000 yuan per box. The ingredients of the drug are basically the same as those of the original drug, but there are certain differences from the original drug in terms of purchasing channels, supervision and drug quality control.

For domestic patients, if they consider using vorsidenib, they need to fully understand the risks and legal issues of purchasing drugs overseas. Although overseas original drugs and generic drugs can be used as potential options, medication regimens should be determined under the guidance of professional doctors and drugs should be obtained through legal and reliable channels. At the same time, patients and their families need to comprehensively consider drug efficacy, price, transportation risks and regulatory compliance to ensure drug safety and therapeutic effect.

Reference link:https://www.drugs.com